Jane Street Group LLC Raises Holdings in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Jane Street Group LLC lifted its position in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 1.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 144,575 shares of the biopharmaceutical company’s stock after purchasing an additional 1,640 shares during the quarter. Jane Street Group LLC owned about 0.30% of Theravance Biopharma worth $1,165,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Quantbot Technologies LP bought a new stake in Theravance Biopharma in the 3rd quarter worth approximately $60,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Theravance Biopharma by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 9,409 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 3,696 shares in the last quarter. Hsbc Holdings PLC bought a new stake in Theravance Biopharma in the second quarter worth $108,000. Ballentine Partners LLC purchased a new stake in Theravance Biopharma during the third quarter valued at $104,000. Finally, XTX Topco Ltd bought a new position in Theravance Biopharma during the second quarter valued at $129,000. 99.10% of the stock is currently owned by hedge funds and other institutional investors.

Theravance Biopharma Stock Down 2.7 %

Shares of TBPH opened at $9.59 on Monday. The business has a fifty day moving average of $9.34 and a 200 day moving average of $8.85. The company has a market cap of $471.58 million, a PE ratio of -9.50 and a beta of 0.23. Theravance Biopharma, Inc. has a 52-week low of $7.44 and a 52-week high of $11.71.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.16). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The firm had revenue of $16.87 million during the quarter, compared to the consensus estimate of $16.11 million. During the same quarter last year, the business posted ($0.17) EPS. As a group, research analysts anticipate that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of Theravance Biopharma in a report on Monday, September 16th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $13.75.

Insider Buying and Selling at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $9.00, for a total value of $36,000.00. Following the sale, the senior vice president now owns 322,743 shares in the company, valued at $2,904,687. This trade represents a 1.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 6.90% of the company’s stock.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.